載入中
NASDAQHealthcareBiotechnology
最新資料
US$29.73
+US$0.22 · +0.75%
Lakefront Biotherapeutics NV, formerly Galapagos NV, is a biotechnology company that focuses on transforming patient outcomes through scientific innovation. It is dedicated to building a pipeline of medicines for patients with serious diseases in therapeutic areas of unmet need, prioritizing oncology and immunology & inflammation programs. The company's clinical-stage portfolio is anchored by potential first-in-class treatments for autoimmune diseases.
前收盤價
US$29.73
+US$0.22 · +0.75%
盤中時間採用ET。市場資料可能有所延遲。
Lakefront Biotherapeutics NV, formerly Galapagos NV, is a biotechnology company that focuses on transforming patient outcomes through scientific innovation. It is dedicated to building a pipeline of medicines for patients with serious diseases in therapeutic areas of unmet need, prioritizing oncology and immunology & inflammation programs. The company's clinical-stage portfolio is anchored by potential first-in-class treatments for autoimmune diseases.
日內區間
目前US$29.73
52週區間
目前US$29.73
盤中時間採用ET。市場資料可能有所延遲。
Lakefront Biotherapeutics NV, formerly Galapagos NV, is a biotechnology company that focuses on transforming patient outcomes through scientific innovation. It is dedicated to building a pipeline of medicines for patients with serious diseases in therapeutic areas of unmet need, prioritizing oncology and immunology & inflammation programs. The company's clinical-stage portfolio is anchored by potential first-in-class treatments for autoimmune diseases.
日內區間
目前US$29.73
52週區間
目前US$29.73
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（EUR） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 11.12億 EUR | 2.76億 EUR | 2.4億 EUR | 2.41億 EUR | 2.34億 EUR |
| 銷貨成本 | 2973.6萬 EUR | 3486.3萬 EUR | — | — | 3.21億 EUR |
| 毛利 | 10.83億 EUR | 2.41億 EUR | 2.4億 EUR | 2.41億 EUR | −8611.9萬 EUR |
| 研究與開發 | 4.59億 EUR | 3.35億 EUR | 2.41億 EUR | 2.7億 EUR | 3.21億 EUR |
| 銷售、一般及管理費用 | 1.12億 EUR | 9688萬 EUR | 9425.2萬 EUR | 1.03億 EUR | 1.32億 EUR |
| 營業費用 | 5.81億 EUR | 4.29億 EUR | 3.28億 EUR | 3.72億 EUR | 8544.9萬 EUR |
| 利息收入 | 4633.9萬 EUR | 8977.3萬 EUR | 7960.8萬 EUR | 1809.4萬 EUR | — |
| 利息支出 | 221.7萬 EUR | 91.1萬 EUR | 177萬 EUR | 915.5萬 EUR | 872.7萬 EUR |
| 折舊和攤銷 | 5587.5萬 EUR | 4549.9萬 EUR | 4364.2萬 EUR | 6556.6萬 EUR | 831.3萬 EUR |
| 營業利益 | 5.01億 EUR | −1.88億 EUR | −8826.3萬 EUR | −1.31億 EUR | −1.72億 EUR |
| 淨利 | 3.21億 EUR | 7408.2萬 EUR | 2.12億 EUR | −2.18億 EUR | −1.03億 EUR |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$35.50
上漲空間 19.41%報告持有此股票曝險的交易所交易基金。
iShares Biotechnology ETFIBB994.06萬0.09%108.2億 USD0.44%US$206.49+3.00%
Schwab International Small-Cap Equity ETFSCHC296.93萬0.05%55.33億 USD0.06%US$49.47+0.84%
ALPS Medical Breakthroughs ETFSBIO251.53萬1.31%1.91億 USD0.50%US$55.04+2.03%
State Street SPDR Portfolio Developed World ex-US ETFSPDW144.17萬0.00%404.62億 USD0.03%US$49.98+0.64%
State Street SPDR S&P International Small Cap ETFGWX63.96萬0.07%9.08億 USD0.40%US$45.56+0.93%
State Street SPDR Portfolio Europe ETFSPEU5.3萬0.01%6.83億 USD0.07%US$53.13+0.68%
ProShares Ultra Nasdaq BiotechnologyBIB1.7萬0.02%9320.36萬 USD1.19%US$110.98+5.68%iShares Biotechnology ETFIBBSchwab International Small-Cap Equity ETFSCHCALPS Medical Breakthroughs ETFSBIOState Street SPDR Portfolio Developed World ex-US ETFSPDWState Street SPDR S&P International Small Cap ETFGWXState Street SPDR Portfolio Europe ETFSPEUProShares Ultra Nasdaq BiotechnologyBIBAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
